SCLX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -229.58% compared to Scilex Holding's net margin of --. Scilex Holding's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 2229.06%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 406.27%. Given that Scilex Holding has higher upside potential than Perspective Therapeutics, analysts believe Scilex Holding is more attractive than Perspective Therapeutics.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Scilex Holding's net income of -$37.6M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Scilex Holding's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 0.88x versus 17.23x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -229.58% compared to Scilex Holding's net margin of 10.05%. Scilex Holding's return on equity of -- beat Electromed's return on equity of 15.62%.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 2229.06%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 12.86%. Given that Scilex Holding has higher upside potential than Electromed, analysts believe Scilex Holding is more attractive than Electromed.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are larger than Electromed quarterly revenues of $14.7M. Scilex Holding's net income of -$37.6M is lower than Electromed's net income of $1.5M. Notably, Scilex Holding's price-to-earnings ratio is -- while Electromed's PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 0.88x versus 4.57x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -229.58% compared to Scilex Holding's net margin of -10.5%. Scilex Holding's return on equity of -- beat Myomo's return on equity of -84.04%.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 2229.06%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 20.36%. Given that Scilex Holding has higher upside potential than Myomo, analysts believe Scilex Holding is more attractive than Myomo.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are larger than Myomo quarterly revenues of $9.2M. Scilex Holding's net income of -$37.6M is lower than Myomo's net income of -$966.4K. Notably, Scilex Holding's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 0.88x versus 9.30x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -229.58% compared to Scilex Holding's net margin of -17.98%. Scilex Holding's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Scilex Holding has a consensus price target of $9.08, signalling upside risk potential of 2229.06%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 384.81%. Given that Scilex Holding has higher upside potential than Xtant Medical Holdings, analysts believe Scilex Holding is more attractive than Xtant Medical Holdings.

Scilex Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Scilex Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scilex Holding pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Scilex Holding quarterly revenues are $16.4M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Scilex Holding's net income of -$37.6M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Scilex Holding's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scilex Holding is 0.88x versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.